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Abstract
Cannabinoid ligands show therapeutic potential in a variety of disorders including anxiety. However, the anxiety-related effects
of cannabinoids remain controversial as agonists show opposite effects in mice and rats. Here we compared the effects of the
cannabinoid agonist WIN-55,212 and the CB1 antagonist AM-251 in CD1 mice and Wistar rats. Special attention was paid to
antagonist–agonist interactions, which had not yet been studied in rats. In mice, WIN-55,212 decreased whereas AM-251 increased
anxiety. The antagonist abolished the effects of the agonist. In contrast, WIN-55,212 increased anxiety in rats. Surprisingly, the
antagonist potentiated this effect. Cannabinoids affect both GABAergic and glutamatergic functions, which play opposite roles in
anxiety. We hypothesized that discrepant ﬁndings resulted from species differences in the relative responsiveness of the two
transmitter systems to cannabinoids. We investigated this hypothesis by studying the effects of WIN-55,212 on evoked hippocampal
inhibitory and excitatory postsynaptic currents (IPSCs and EPSCs). IPSCs were one order of magnitude more sensitive to WIN-
55,212 in mice than in rats. In mice, IPSCs were more sensitive than EPSCs to WIN-55,212. This is the ﬁrst study showing that the
relative cannabinoid sensitivity of GABA and glutamate neurotransmission is species-dependent. Based on behavioural and
electrophysiological ﬁndings, we hypothesize that WIN-55,212 reduced anxiety in mice by affecting GABA neurotransmission
whereas it increased anxiety in rats via glutamatergic mechanisms. In rats, AM-251 potentiated this anxiogenic effect by inhibiting the
anxiolytic GABAergic mechanism. We suggest that the anxiety-related effects of cannabinoids depend on the relative cannabinoid
responsiveness of GABAergic and glutamatergic neurotransmission.
Introduction
The identiﬁcation of cannabinoid receptors and their endogenous
ligands triggered an exponential growth in studies exploring the
endocannabinoid system and its regulatory functions in health and
disease (Pacher et al., 2006). Cannabinoid ligands have therapeutic
potential in a wide range of pathological conditions, including anxiety.
However, the anxiety-related effects of cannabinoids are controversial,
especially when data obtained in different species are compared.
In mice, anxiety is increased by both the genetic disruption of the
CB1 receptor and its pharmacological blockade by AM-251 (Haller
et al., 2002, 2004a, 2004b; Maccarrone et al., 2002; Martin et al.,
2002; Uriguen et al., 2004; Rodgers et al., 2005; Patel & Hillard,
2006). In line with the effects of CB1 blockade, cannabinoid agonists
(D9-tetrahydrocannabinol, WIN-55,212, and CP 55 940) decreased
anxiety in mice (Berrendero & Maldonado, 2002; Valjent et al., 2002;
Haller et al., 2004b; Patel & Hillard, 2006). Although conﬂicting data
are reported with the antagonist SR-141716A (Haller et al., 2002;
Rodgers et al., 2003; Griebel et al., 2005; Patel & Hillard, 2006),
taken together, data suggest that cannabinoids mediate anxiolysis in
mice. Antagonists and agonists were rarely applied together, but two
studies suggest that the former abolish the effects of the latter, i.e. the
effects are mediated by the CB1 receptor (Berrendero & Maldonado,
2002; Haller et al., 2004b).
In contrast to mice, nonsedative doses of CB1 agonists (AM-411,
CP-55,940 and HU-210) increased anxiety in the elevated plus-maze,
social interaction, open ﬁeld and defensive withdrawal tests in Wistar,
Sprague–Dawley, hooded Lister and Long–Evans rats (Rodriguez de
Fonseca et al., 1996; Giuliani et al., 2000; Arevalo et al., 2001; Marin
et al., 2003; Genn et al., 2004; Hill & Gorzalka, 2004; Marco et al.,
2004; McLaughlin et al., 2005). Two studies suggest that the
antagonist SR-141716A is also anxiogenic in rats (Arevalo et al.,
2001; Navarro et al., 1997). Surprisingly, antagonist–agonist interac-
tions were not studied in this species. Although the lack of such
studies casts doubt on the conclusion, data obtained with agonists
suggest that cannabinoids mediate anxiogenic effects in rats.
In the present study, we compared the effects of the cannabinoid
agonist WIN-55,212 and the CB1 antagonist AM-251 in CD1 mice
and Wistar rats, strains that have been frequently studied. Special
attention was paid to antagonist–agonist interactions, which are largely
unknown in rats. The impact of experimental conditions was also
studied. Our ﬁndings conﬁrmed the species-dependent effects of
cannabinoids; moreover, we revealed a paradoxical antagonist–agonist
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glutamatergic and gamma-aminobutyric acid (GABA) ergic mecha-
nisms (Ha ´jos et al., 2001; Ha ´jos & Freund, 2002; Piomelli, 2003),
which play opposite roles in anxiety (Millan, 2003), we hypothesized
that the species-dependent effects of cannabinoids on anxiety depend
on differences in the cannabinoid sensitivity of glutamatergic and
GABAergic neurotransmission. This hypothesis was investigated by
comparing the effects of WIN-55,212 on hippocampal excitatory and
inhibitory postsynaptic currents in mice and rats.
Materials and methods
Experimental animals
Subjects were CD1 mice and Wistar rats obtained from Charles River
Laboratories (Budapest, Hungary). Approximately two-month-old
mice (body weight was  35 g) and two-month-old rats (body weight
was  300 g) were used. Animals were acclimatized to local
conditions for at least 1 week. Food and water were available ad
libitum. Temperature and humidity were 23 ± 2  C and 60 ± 10%,
respectively. Experiments were conducted in both the light and dark
phases of the day. Mice establish strong dominance hierarchies, and
social status affects anxiety in this species (Ferrari et al., 1998). To
avoid confounds from social status, subjects were kept in individual
cages for 2 weeks prior to experimentation. The impact of housing
conditions was also studied in rats.
Experiments were carried out in accordance with the European
Communities Council Directive of 24 November 1986 (86⁄609⁄EEC)
and were reviewed and approved by the Animal Welfare Committee of
the Institute of Experimental Medicine.
Behavioural studies
Both the mouse and the rat plus-maze were made of dark grey painted
wood. The dimensions of the apparatus were adapted to the size of the
species (mice: arm length 30 cm, arm width 7 cm, wall height 30 cm
and platform height 80 cm; rats: arm length 50 cm, arm width 17 cm,
wall height 30 cm and platform height 80 cm). Open arms were
surrounded by 0.3- and 0.5-cm-high ledges in mice and rats,
respectively. Subjects were placed in the central area of the apparatus
with head facing a closed arm. Exposure lasted 5 min. Closed-arm
entries were considered indicators of locomotor activity whereas open-
arm exploration was used as a measure of anxiety. Open arm
exploration was characterized by two variables: percentage time spent
in the open arm, and percentage open arm entries (100 · open arm
entries/total arm entries).
It has been shown that mice are sensitive to cannabinoid effects
only when the plus-maze is brightly lit (Haller et al., 2004a).
Therefore, mice were tested under intense light (four white lamps of
40 W each;  200 lux). Similar illumination is strongly anxiogenic in
rats. Therefore, the rat plus-maze was illuminated by a red lamp of
40 W (  1 lux) in the ﬁrst experiments. Separate studies were run to
investigate the impact of illumination. The effects of the diurnal cycle
were also investigated.
WIN-55,212 and AM-251 were obtained from Tocris Cookson Ltd
(UK), and were dissolved in dimethyl sulphoxide (DMSO) ﬁrst, and
diluted with 0.4% methylcellulose (in saline) to the ﬁnal volume. The
concentration of DMSO was <1.5% in the ﬁnal solution. Controls
received DMSO-containing methylcellulose in similar concentrations.
Combined treatments involved the i.p. injection of a mixture of the
two compounds (i.e. one injection was given). Chlordiazepoxide
(Sigma, Budapest, Hungary) was dissolved in 0.4% methylcellulose,
and injected i.p.
Experiments 1 and 2 investigated the effects of the CB1 antagonist
AM-251 in mice (N ¼ 11 or 12 per group) and rats (N ¼ 9 or 10 per
group). These experiments were conducted according to the protocols
used earlier in our laboratory (mice: light phase of the day, social
isolation, strongly illuminated plus-maze; rats: dark phase of the day,
group housing, dimly illuminated plus-maze). The impact of experi-
mental conditions was studied in experiments 5–7.
Experiment 3 evaluated in mice the effects of the cannabinoid
agonist WIN-55,212 alone or in combination with the antagonist
AM-251. Two experiments were performed. Experiment 3a assessed
the effect of WIN-55,212 (1 and 3 mg⁄kg; N ¼ 10 per group). In
Experiment 3b, the effects of the large WIN-55,212 dose (3 mg⁄kg)
was investigated alone or in combination with a low dose of the
antagonist that was without effect on its own (0.5 mg⁄kg; N ¼ 10 per
group).
The effects of WIN-55,212 in rats were studied in Experiment 4.
Experiment 4a (N ¼ 8 per group) assessed the effects of a small and a
large dose (0.1 and 1 mg⁄kg, respectively). As the effects were
opposite to those seen in mice, intermediate doses (0.3 and
0.5 mg⁄kg; N ¼ 12) and a larger dose (3 mg⁄kg; N ¼ 8) were also
investigated (Experiment 4b). Thus, the effects of the agonist were
studied over a large dose range (0.1–3 mg⁄kg).
Experiments 5–7 were performed to evaluate the impact of
experimental conditions on cannabinoid responsiveness in rats. In
Experiment 5, we administered WIN-55,212 in the light phase of the
day to rats maintained in social isolation (N ¼ 10 per group). Plus-
maze testing was performed under dim red light. Experiment 6
assessed the effects of the same agonist during the light phase in rats
maintained in social isolation, the plus-maze testing being performed
under high white light (N ¼ 9 or 10 per group). In Experiment 7, we
studied the effects of AM-251 during the light phase of the day in rats
maintained in social isolation (N ¼ 9 per group).
The antagonist–agonist interaction in rats was examined in
Experiment 8. We treated rats with 0.3 and 1 mg⁄kg WIN-55,212
alone or in combination with 1 mg AM-251 (N ¼ 8 per group). It is
noteworthy that AM-251 alone did not affect behaviour in rats.
Experiment 9. To rule out the possibility that differences seen
with cannabinoid ligands were due to intrinsic species differences in
response to anxiolytics, we studied the response of both mice and
rats to the anxiolytic chlordiazepoxide in the elevated plus-maze.
Conditions were similar with those employed in Experiments 1
and 2.
Electrophysiology
Horizontal slices of the hippocampus (400 lm thick) were prepared
from Wistar rats (14–17 days old) or 350-lm-thick sections from CD1
mice (15–25 days old) as described elsewhere (Ha ´jos & Freund,
2002). Animals were anesthetized by isoﬂuran inhalation. Slices were
incubated for ‡1 h in ACSF at room temperature in an interface-type
chamber, and then transferred to a submerged-type recording chamber.
Whole-cell patch-clamp recordings were obtained at 30–32  C from
CA1 pyramidal cells visualized by infrared DIC videomicroscopy
(Zeiss Axioscope, Germany) using a ﬂow rate of 3–4 mL⁄min in a
slice chamber optimized for laminar ﬂow to ensure the stability of the
amplitude of evoked currents. The extracellular solution (artiﬁcial
cerebrospinal ﬂuid; ACSF) had a composition of (in mm) NaCl, 126;
KCl, 2.5; NaHCO3, 26; CaCl2, 2; MgCl2, 2; NaH2PO4, 1.25; and
glucose, 10; the intrapipette solution contained (in mm) CsCl, 80; Cs-
gluconate, 60; NaCl, 3; MgCl2, 1; HEPES, 10; Mg-ATP, 2; and QX-
314, 5 (pH 7.2–7.3 adjusted with CsOH; osmolarity 275–290 mOsm).
To isolate the excitatory (E) postsynaptic currents (PSCs), slices were
2446 J. Haller et al.
ª The Authors (2007). Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd
European Journal of Neuroscience, 25, 2445–2456perfused with ACSF containing 70–100 lm picrotoxin to block
GABAA receptor-mediated transmission. To record inhibitory postsy-
naptic currents (IPSCs), the ACSF contained 2–3 mm kynurenic acid
to eliminate ionotropic glutamatergic transmission. Recordings were
made at a holding potential of )65 mV. Electrical stimulation was
delivered, via a theta glass pipette (Sutter Instruments) containing
ACSF, at 0.1 Hz using a Supertech timer and isolator (Supertech LTD,
Pe ´cs, Hungary). To evoke EPSCs, the pipette was placed into the
stratum radiatum while IPSCs were evoked by an electrode placed into
the stratum pyramidale. Access resistances (between 4 and 18 MW,
compensated 65–70%) were frequently monitored and remained
constant (±20%) during the period of analysis. Signals were recorded
with a Multiclamp 700A (Axon Instruments, CA, USA), ﬁltered at
2 kHz, digitized at 6–10 kHz (PCI-6024E A⁄D board; National
Instruments, Austin, TX, USA) and analysed off-line with the EVAN
program (courtesy of I. Mody, UCLA, CA, USA). The rising and the
decaying phases of averaged PSCs were ﬁtted with a single exponential
function.
Only the effects of WIN-55,212 were studied, as AM-251 per se
does not affect postsynaptic currents (Kreitzer & Regehr, 2001;
Nakatsuka et al., 2003; Ha ´jos et al., 2004). We have shown earlier that
HCl solvent ensures a greater stability of the response in electro-
physiological experiments (Ha ´jos & Freund, 2002). Therefore, WIN-
55,212 (Sigma) was dissolved in 0.1 n HCl to give a 20 mm stock
solution. From this stock solution, the ﬁnal dilution of WIN-55,212
was made in ACSF containing either kynurenic acid or picrotoxin
under constant stirring, and the prepared solution was bath-applied.
The drug was superfused until the maximal effect was seen. Usually
this took 6–8 min. To quantify the drug effects, control PSC
amplitudes in a 2- to 3-min time window were compared with those
measured after 10 min drug application for the same period of time.
To avoid the possible effect of the change in pH, we added the same
amount of HCl to the control solution. Only those experiments were
included that had stable amplitude for at least 10 min before drug
application. After each experiment, the tubing made of Teﬂon was
washed with ethanol for 10 min and with ACSF for 15 min. Each data
point represents the mean ± SEM of the maximal inhibition of the
evoked PSCs (n ¼ 3–5).
One animal per day was studied, and the species was randomly
chosen for the particular day. Similarly in both species, three animals
each were tested with the low and high concentrations, and four or ﬁve
animals with intermediate concentrations. On average, three record-
ings per animal were performed and two different concentrations were
examined.
Immunocytochemistry
Male Wistar rats and CD1 mice were deeply anaesthetized with
Equithesin (0.3 mL⁄100 g), and perfused ﬁrst with physiological
saline (2 min), and then with 100 or 400 mL (mice and rats,
respectively) ﬁxative containing 0.05% glutaraldehyde (TAAB
Laboratory Equipment, Berks, UK), 4% paraformaldehyde (Sigma)
and 0.2% picric acid in 0.1 m phosphate buffer (PB; pH 7.4) for
30 min. After ﬁxation, brains were removed from the skull and were
postﬁxed in the same ﬁxative for 1 h. Blocks containing the dorsal
hippocampus were sectioned on a Vibratome at 50 lm, then washed
extensively in PB. Sections from the left and right hemispheres were
incubated separately. All sections were incubated ﬁrst in a blocking
solution containing 3% bovine serum albumin (Sigma) and 0.5%
Triton X-100 (Sigma) for 1 h. The CB1 receptors were stained with
the antibody (diluted 1 : 1000) for 2 days at 4  C; it was raised against
a glutathione S-transferase fusion protein containing the entire C-
terminus of the rat CB1 receptor. It has been shown that this antibody
reliably labels receptors located on GABAergic cells but does not label
CB1 receptors located on glutamatergic neurons (Katona et al., 1999,
2001; Ha ´jos et al., 2000; Ma ´tya ´set al., 2004; Bodor et al., 2005; Nyı ´ri
et al., 2005). The speciﬁcity of the antisera and the method was
conﬁrmed in CB1-knockout (-KO) animals, as in an earlier study of
our lab (Ha ´jos et al., 2000). All the washing steps (3 · 10 min) and
the dilution of the antisera were performed in 50 mm Tris-buffered
saline (TBS; pH 7.4). Sections were then incubated in Alexa 594-
conjugated goat antirabbit IgG (1 : 200; Molecular Probes, Eugene,
OR, USA) for 2 h at room temperature. Sections were again washed in
TBS, mounted in Vectashield to retard ﬂuorescence fading, and then
cover-slipped.
Five sections each from three mice and three rats were paired in
such a way that sections from the two species were processed together
in the same vials. The immunostaining protocol was thus carried out in
15 vials in parallel, and analysed at the same time to avoid bleaching
of the ﬂuorescent dye.
One image from randomly selected areas of both surfaces (areas
spanning from the CA1 alveus to the middle of the dentate hilus, at a
width of  200–300 lm) of ﬁve sections each (mice and rats) from the
hippocampi were captured at a depth of 3 lm from the section surface
on an Olympus FV300-BX confocal laser-scanning microscope with a
40· objective with a numerical aperture of 3. We used the publicly
available morphometry program ImageJ to measure the density of
CB1 labelling in the distinct layers of CA1 and dentate gyrus. To make
our data simpler to understand, we inverted the grayness values. Thus,
the value 0 indicated no staining (white) while the value 255 referred
to the darkest staining (black), i.e. higher grayness corresponds to
stronger staining. We analysed the mean grey value of each image.
Data from left and right sections, as well as upper and lower surface
images of the same species, did not differ signiﬁcantly and were
pooled. Thus, a total of 120 images from the dentate gyrus and CA1 of
mice and rats were analysed and resulted in 30 pooled images (15 each
of mice and rats), which were then statistically compared.
Statistics
Behavioural, electrophysiological and immunocytochemical data were
analysed using anova. The homogeneity of variances was tested by
the Levene test, and data underwent square-root transformation where
necessary. The Fisher LSD test was used for pairwise comparisons.
Results
The effects of the CB1 antagonist AM-251 in mice and rats
In mice, the CB1 receptor antagonist AM-251 had a clear anxiogenic
effect without affecting locomotion (Fig. 1A). Closed-arm entries were
not affected signiﬁcantly (F4,65 ¼ 1.41; P > 0.2), whereas the time
spent in the open arms and percentage of open-arm entries were
marginally and signiﬁcantly reduced, respectively (F4,65 ¼ 2.42,
P ¼ 0.057; F4,65 ¼ 4.79, P < 0.003). Open-arm entries were also
signiﬁcantlyreduced,from7.30 ± 1.09seenincontrolsto2.42 ± 0.7in
the group treated with 3 mg⁄kg AM-251 (F4,65 ¼ 5.41; P < 0.001).
In contrast, rats responded poorly to AM-251; a wider dose range
(0.1–5 mg⁄kg vs. 0.3–3 mg⁄kg) failed to induce signiﬁcant changes
in plus-maze behaviour (closed-arm entries, F3,34 ¼ 0.76, P < 0.5;
percentage of open-arm time, F3,34 ¼ 0.46; P < 0.7; percentage of
open-arm entries, F3,34 ¼ 0.48, P < 0.7; Fig. 1B).
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The cannabinoid agonist WIN-55,212 produced clear anxiolytic effects
in mice (Fig. 2). Locomotor behaviour was not affected (F2,27 ¼ 0.64,
P < 0.5). In contrast, open-arm exploration was increased
(F2,27 ¼ 4.94, P < 0.02 and F2,27 ¼ 2.94, P < 0.07, for duration and
percentage of open-arm visits, respectively). In Experiment 3b, the
agonist WIN-55,212 again reduced anxiety without affecting locomo-
tion(closed-armentries,F2,27 ¼ 0.31;P > 0.7;percentageofopen-arm
time, F2,27 ¼ 5.23; P < 0.01; percentage of open-arm entries,
F2,27 ¼ 4.51; P < 0.02). The low dose of AM-251 (0.5 mg⁄kg)
abolished the effects of the agonist on percentage of open-arm time
whereas the increase in percentage of open-arm entries was marginally
reduced (P<0.1). The group treated with WIN-55,212 and AM-251
did not differ signiﬁcantly from controls in either variable.
The effects of WIN-55,212 in rats
The effects of WIN-55,212 in rats were opposite to those seen in mice
(Fig. 3). In Experiment 4a, the 0.1 mg⁄kg dose had no signiﬁcant
effect on behaviour whereas the larger dose (1 mg⁄kg) was clearly
anxiogenic, with no signiﬁcant effect on locomotion (closed-arm
entries, F2,21 ¼ 1.44, P < 0.3; percentage of open-arm time,
F2,21 ¼ 3.29, P < 0.05; percentage of open-arm entries,
F2,21 ¼ 6.34, P < 0.007). In Experiment 4b, intermediate doses (0.3
and 0.5 mg⁄kg) had minor effects on behaviour whereas a larger dose
(3 mg⁄kg) was also anxiogenic (closed-arm entries, F1,13 ¼ 1.20,
P < 0.3; percentage of open-arm time, F1,13 ¼ 5.56, P < 0.04;
percentage of open-arm entries, F1,13 ¼ 7.10, P < 0.02).
Experimental conditions affected plus-maze behaviour (e.g. intense
light increased anxiety) but did not inﬂuence the effects of cannabi-
noids. WIN-55,212 was clearly anxiogenic in individually housed rats
that were assessed during the passive (light) phase of the day under
dim light (closed-arm entries, F2,27 ¼ 0.60, P < 0.6; percentage of
open-arm time, F2,27 ¼ 3.85, P < 0.0033; percentage of open-arm
entries, F2,27 ¼ 4.68, P < 0.017; Fig. 4A). Open-arm exploration was
very low when socially isolated rats were studied during the light
phase of the day and were tested under intense light (Fig. 4B). This
precluded the expression of signiﬁcant anxiogenic effects. The
nonsigniﬁcant changes, however, were consistent with increased
anxiety. This conclusion was supported by signiﬁcant changes in the
time spent in the closed arms and the central area. At 3 mg⁄kg, WIN-
55,212 increased the percentage of closed-arm time (controls,
54.5 ± 6.1; 0.3 mg⁄kg WIN-55,212, 53.4 ± 5.1; 3 mg⁄kg WIN-
55,212, 73.5 ± 6.0%; F2,26 ¼ 3.74, P < 0.037) and decreased the
percentage of time spent in the central area (a less safe compartment of
the plus-maze; controls, 40.5 ± 4.6; 0.3 mg⁄kg WIN-55,212,
45.2 ± 4.8; 3 mg⁄kg WIN-55,212, 25.9 ± 5.7%; F2,26 ¼ 3.86,
P < 0.033). The preference for the safest compartment (closed-arm)
and the avoidance of the less safe central area suggest that the
compound was anxiogenic under these conditions as well.
AM-251 did not affect behaviour when tested in the light phase of
the day (closed-arm entries, F2,24 ¼ 0.38; P < 0.7; percentage of
open-arm time, F2,24 ¼ 0.42; P < 0.7; percentage of open-arm entries,
F2,24 ¼ 0.06; P < 09; Fig. 4C).
AM-251–WIN-55,212 interactions in rats
In line with the ﬁndings presented above, 0.3 mg⁄kg WIN-55,212 had
no effects on plus-maze behaviour, whereas 1 mg⁄kg was anxiogenic
(Fig. 5; percentage of open-arm time, F4,35 ¼ 4.90; P < 0.003;
percentage of open-arm entries, F4,35 ¼ 3.01; P < 0.03). Closed-arm
entries were not affected. AM-251 did not prevent the effects of
1m g⁄kg WIN-55,212. Surprisingly, the low dose of the agonist
(ineffective per se) signiﬁcantly increased anxiety when coadminis-
tered with AM-251. Thus, the antagonist potentiated the effects of the
agonist. The experiment was repeated with a slightly larger WIN-
55,212 dose (0.5 mg⁄kg). Again the agonist had no effects on its own
but increased anxiety when coadministered with AM-251 (data not
shown).
The effects of chlordiazepoxide in mice and rats
Chlordiazepoxide dose-dependently reduced anxiety in both mice and
rats (Table 1). Anxiolytic doses had no signiﬁcant effect on
locomotion but higher doses suppressed locomotion in both species.
WIN-55,212 sensitivity of evoked postsynaptic currents
Under our conditions, WIN-55,212 was able to reduce the amplitude
of both IPSCs and EPSCs by at most half (Fig. 6). In mice, IPSCs
were almost one order of magnitude more sensitive than EPSCs to the
Fig. 1. AM-251 increased anxiety-like behaviour in (A) mice without
affecting it in (B) rats. *P < 0.05, at least, compared with vehicle control.
Additional experiments showed that the slight (not signiﬁcant) effects seen in
rats were due to chance (see Fig. 4).
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larger sensitivity to WIN-55,212 than did those in rats. In mice, the
estimated EC50 values of the ﬁtted curves were 0.15 and 0.97 nm for
IPSCs and EPSCs, respectively. In rats, estimated EC50 values were
0.89 and 0.88 nm for IPSCs and EPSCs, respectively.
In contrast to the difference in pharmacological sensitivity of
inhibitory synapses, the properties of IPSCs in control conditions were
similar inmice(n ¼ 15) andrats(n ¼ 16;amplitude, 431.4 ± 62.1and
431.8 ± 44.8 pA in mice and rats, respectively; F1,29 ¼ 0.01, P > 0.9;
risetime,1.15 ± 0.21and1.16 ± 0.35 msinmiceandrats,respectively;
F1,29 ¼ 0.01, P > 0.9; decay time constant, 11.8 ± 0.8 and
10.9 ± 0.9 ms in mice and rats, respectively; F1,29 ¼ 0.41, P > 0.5).
EPSCswerealsosimilarinthetwospecies(amplitude,198.1 ± 32.2and
295.6 ± 38.7 pAinmiceandrats,respectively;F1,29 ¼ 3.76,P > 0.05;
rise time, 3.5 ± 0.39 and 2.86 ± 0.3 ms in mice and rats, respectively;
F1,29 ¼ 1.73; P > 0.1, decay time constant, 12.6 ± 1.3 and
13.9 ± 2.1 ms in mice and rats, respectively; F1,29 ¼ 0.3, P > 0.5).
The efﬁcacy of WIN-55,212 in hippocampal slices: a note on
earlier and present ﬁndings
In the present experiments, the effects of WIN-55,212 were similar to
those seen earlier but were produced at 100-fold lower concentrations
(Hoffman & Lupica, 2000; Ha ´jos & Freund, 2002). Importantly, we
used here and in our previous study (Ha ´jos & Freund, 2002) animals
from the same source, the same electrophysiological equipment and
the same solvent for WIN-55,212. However, the preparation and
storage of slices, as well as the ﬂow rate of the solution during
recordings, were altered: slices were kept in an interface-type
chamber before recordings, and a higher ﬂow rate was used in the
recording chamber. This ensured better oxygenation of the tissue
(Ha ´jos et al., 2005). In addition, the amplitude of evoked synaptic
currents became more stable under these conditions. We performed
additional experiments to compare endocannabinoid signalling in
slices stored in submerged vs. interface chambers. We found not only
that the efﬁcacy of WIN-55,212 was markedly increased in the
latter, but also that depolarization-induced suppression of inhibition,
known to involve CB1 receptors, was more stable and enhanced
(N. Hajos, unpublished observations). We believe that the changes in
the in vitro experimental conditions might better approximate the
in vivo conditions. It is noteworthy that the present data are in line
with those measured in cell cultures (Ohno-Shosaku et al., 2002) and
binding assays (Felder et al., 1995).
Immunocytochemistry
The general features of CB1 staining in mice and rats have been
described in detail earlier (Freund et al., 2003; Ma ´tya ´s et al., 2004).
Therefore, we focused only on species differences in this study. We
stress again that the antibody used here visualized CB1 receptors
located on GABAergic neurons (see above).
In the stratum granulosum of the dentate gyrus, stronger staining was
obtained in rats than in mice (F1,8 ¼ 22.41, P ¼ 0.0014; Fig. 7). When
the stratum moleculare was taken as a whole, no signiﬁcant differences
occurred (F1,8 ¼ 0.24, P > 0.5). However, the inner third and outer
two-thirdsofthestratummoleculareshowedspecies-relateddifferences
when analysed separately. Staining was stronger in the mouse inner
stratum moleculare (F1,8 ¼ 22.99; P ¼ 0.0013). A smaller, but still
signiﬁcant, difference was seen in the outer two-thirds of stratum
moleculare,nowinfavour ofrats(F1,8 ¼ 7.63,P ¼ 0.024). IntheCA1
region, staining was signiﬁcantly stronger in the stratum pyramidale of
mice than of rats (F1,8 ¼ 6.07, P ¼ 0.039). In the stratum radiatum, the
difference was marginally signiﬁcant (F1,8 ¼ 3.94, P ¼ 0.08).
Discussion
We found that cannabinoid ligands have opposite effects on anxiety
in mice and rats. In mice, the cannabinoid agonist WIN-55,212
produced anxiolytic effects which were readily abolished by the CB1
antagonist AM-251. In rats, the agonist was anxiogenic, an effect
that was, surprisingly, potentiated by the antagonist. It is noteworthy
that the reference compound used in this study (chlordiazepoxide)
dose-dependently decreased anxiety in both species. The relative
Fig. 2. The cannabinoid agonist WIN-55,212 (WIN) decreased anxiety-like behaviour in the mouse elevated plus-maze and the effect was abolished by the speciﬁc
CB1 receptor antagonist AM-251 (AM). Data are derived from two different experiments in which statistical analysis was run separately (see Results). For clarity,
data are presented here as differences from vehicle control. *P < 0.05, at least, vs. vehicle control;
#P < 0.05 vs. WIN-55,212, 3 mg ⁄ kg;
+, marginally signiﬁcant
difference (0.05 <
+P<0.1) from WIN-55.212, 3 mg ⁄ kg.
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EPSCs also showed marked species differences.
Comparison with earlier ﬁndings
Our study conﬁrms earlier ﬁndings on the contrasting effects of
cannabinoids in mice and rats. CB1 knockouts as well as wild-type
mice treated with AM-251 showed anxiety in various tests, whereas
cannabinoid agonists decreased anxiety (Berrendero & Maldonado,
2002; Haller et al., 2002, 2004a, 2004b; Maccarrone et al., 2002;
Martin et al., 2002; Valjent et al., 2002; Uriguen et al., 2004; Rodgers
et al., 2005; Patel & Hillard, 2006). In addition, the antagonist
abolished the effects of the agonist in two studies (Berrendero &
Maldonado, 2002; Haller et al., 2004a). Thus, our ﬁndings in mice are
Fig. 4. Testing conditions had no impact on the effects of cannabinoid ligands
on anxiety in rats. WIN-55,212 remained anxiogenic in individually housed rats
tested in the light phase of the day under both (A) dim and (B) intense light
conditions.Additionaldataonthebehaviourofratsinthelattertestareincludedin
Results. The CB1 antagonist AM-251 had no effects on anxiety in individually
housed rats tested in the light phase of the day (C). *P < 0.05 vs. control.
Fig. 3. The cannabinoid agonist WIN-55,212 increased anxiety-like beha-
viour in the rat elevated plus-maze. (A) Effects on locomotion (closed-arm
entries); (B and C) effects on anxiety (percentage open-arm time and
percentage open-arm entries, respectively). Data are expressed as differences
from control (C). *P < 0.05, at least, vs. control.
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the cannabinoid antagonist SR-141716A (anxiolysis: Haller et al.,
2002; Rodgers et al., 2003; Griebel et al., 2005; anxiogenesis: Patel &
Hillard, 2006). However, SR-141716A, in contrast to AM-251,
affected various functions in CB1-KO mice (including anxiety),
suggesting that this antagonist also affects the putative novel receptor
(Jarai et al., 1999; Breivogel et al., 2001; Ha ´jos et al., 2001; Haller
et al., 2002; Ko ˜falvi et al., 2003).
More intriguing ﬁndings were, however, obtained with rats. There
are virtually no studies investigating the interaction between cannabi-
noid antagonists and agonists in this species. We show here that AM-
251 does not inhibit the anxiogenic effects of WIN-55,212; moreover,
it potentiates the effects of low doses that are ineffective per se.I ti s
noteworthy that the effect of the agonist was consistent with earlier
reports in rats (Arevalo et al., 2001; Rodriguez de Fonseca et al.,
1996; Giuliani et al., 2000; Marin et al., 2003; Genn et al., 2004; Hill
& Gorzalka, 2004; Marco et al., 2004; McLaughlin et al., 2005).
Taken together, our ﬁndings suggest that WIN-55,212 acts via
different mechanisms in the two species.
Mechanisms of cannabinoid action in mice and rats:
a hypothesis
Cannabinoids retrogradely inhibit both glutamate and GABA release
(Ha ´jos et al., 2001; Marsicano & Lutz, 1999; Ha ´jos & Freund, 2002;
Piomelli, 2003; Katona et al., 2006), which play opposite roles in
anxiety (Millan, 2003). We hypothesize that discrepant behavioural
Fig. 5. The CB1 antagonist AM-251 potentiated the effects of the cannabinoid agonist WIN-55,212 on anxiety-like behaviour in rats. Data are expressed as
differences from control (C). The low dose of the agonist (ineffective per se) became anxiogenic when administered together with the antagonist. *P < 0.05, at least,
vs. vehicle control.
Table 1. The effect of the reference compound chlordiazepoxide on the plus-maze behaviour of rats and mice
Group and treatment
Dose
(mg ⁄ kg)
Closed-arm
entries
Time in open
arms (%)
Open-arm
entries (%)
Rats 12.7 ± 0.9 16.5 ± 2.2 37.9 ± 2.8
Vehicle 12.7 ± 0.9 16.5 ± 2.2 37.9 ± 2.8
Chlordiazepoxide 2 15.6 ± 1.4 30.2 ± 4.3* 49.8 ± 4.7
Chlordiazepoxide 3 14.8 ± 1.3 32.1 ± 3.8* 47.8 ± 2.8*
Chlordiazepoxide 5 6.5 ± 0.4* 13.2 ± 3.9 32.8 ± 5.0
Chlordiazepoxide 10 2.0 ± 0.7* 2.8 ± 2.3* 8.9 ± 5.7*
F4,52 14.80 9.57 10.59
P < 0.0001 < 0.0001 < 0.0001
Mice 19.2 ± 0.8 13.2 ± 1.7 35.4 ± 3.0
Vehicle 19.2 ± 0.8 13.2 ± 1.7 35.4 ± 3.0
Chlordiazepoxide 5 23.7 ± 2.3 20.5 ± 3.5 38.3 ± 2.3
Chlordiazepoxide 10 21.1 ± 2.3 22.1 ± 3.5 41.9 ± 4.2
Chlordiazepoxide 15 13.8 ± 1.5 31.9 ± 5.3* 59.7 ± 4.0*
Chlordiazepoxide 20 17.4 ± 2.8 31.1 ± 4.3* 54.8 ± 3.2*
Chlordiazepoxide 25 6.1 ± 2.3* 49.4 ± 12.6* 45.6 ± 7.0
F5,51 8.92 3.96 4.87
P < 0.0001 < 0.005 < 0.001
Chlordiazepoxide dose-dependently reduced anxiety in both mice and rats without affecting locomotion at anxiolytic doses; *P < 0.05 at least.
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glutamatergic and GABAergic neurotransmission in Wistar rats and
CD1 mice (Fig. 8).
As shown earlier, WIN-55,212 inhibits both IPSCs and EPSCs in
the hippocampus (Ha ´jos & Freund, 2002). Thus, the agonist affects
both GABA and glutamate neurotransmission. AM-251 abolished the
WIN-55,212-induced inhibition of IPSCs but not of EPSCs, strongly
suggesting that this antagonist is active on GABAergic but not on
glutamatergic neurons. The discrepancy might be related to the
distinctive features of CB1 receptors located on GABAergic and
glutamatergic neurons (Katona et al., 2006). Taken together, these
considerations suggest that AM-251 inhibits those effects of WIN-
55,212 mediated by GABAergic but not glutamatergic neurons.
In mice, anxiety appears to be decreased by WIN-55,212 via CB1
receptors located on GABAergic neurons, as the effect was readily
abolished by AM-251. We suggest that, in rats, the WIN-55,212-
induced anxiety was mediated by glutamatergic mechanisms, as
AM-251 did not inhibit this effect. Nevertheless, one can assume that
WIN-55,212 still affected GABA neurotransmission in rats, which
may explain the antagonist-induced potentiation of the agonist effect
(Fig. 8). When the antagonist and agonist were administered together
in rats, the GABA-mediated anxiolysis was probably inhibited by
AM-251, which enhanced glutamate-mediated anxiogenesis. Our
hypothesis involves glutamate-mediated anxiogenesis by cannabinoids
being stronger than GABA-mediated anxiolysis. Earlier ﬁndings with
SR-141716A indirectly support this assumption. The effects of
SR-141716A on glutamatergic functions persisted in CB1-KO mice,
but its effects on GABAergic mechanisms disappeared in this
genotype (Ha ´jos et al., 2001; Ko ˜falvi et al., 2003). However,
SR-141716A decreased anxiety in both CB1-KOs and wild types,
suggesting that its glutamatergic effects were more important for
anxiety than its GABAergic effects (Haller et al., 2002). It is
noteworthy that SR-141716A, unlike AM-251, inhibited the effects of
WIN-55,212 on both IPSCs and EPSCs.
Our hypothesis is supported by studies concerning the effects of
cannabinoids on baroreceptor input into the n. tractus solitarius
(Rademacher et al., 2003; Seagard et al., 2004). In dogs, the effects of
cannabinoids appeared to be mediated by glutamatergic mechanisms,
whereas both GABAergic and glutamatergic mechanisms were
operational in rats. Patel & Hillard (2006) also suggested that different
Fig. 6. The sensitivity of synaptic inhibition to WIN-55,212 was different in mice and rats. (A) Representative averaged records of 6–9 consecutive events taken
before (black) and after 10 min of drug application (grey) are superimposed. The concentration of WIN-55,212 is indicated for each example. (B) Concentration–
response relationship of WIN-55,212 on the inhibition of evoked IPSCs and EPSCs recorded in CA1 pyramidal cells in mice and rats. The number of data points at
each concentration is indicated above or below the curves for IPSC and EPSCs, respectively. Scale bars, 100 pA and 10 ms for IPSCs, and 50 pA and 10 ms for
EPSCs recorded in rats; 25 pA and 10 ms for EPSCs obtained in mice.
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although they activate the same receptor.
The electrophysiological study strengthened the view that the CB1
receptors involved in the anxiolytic effect of WIN-55,212 were located
on GABAergic neurons in mice, as IPSCs were about one order of
magnitude more sensitive to the action of this compound than were
EPSCs. Naturally, differences in the sensitivity to WIN-55,212
became meaningless if receptors were fully occupied, i.e. both IPSCs
Fig. 7. Comparison of CB1 immunorectivity on GABAergic axons and axon terminals in mouse and rat hippocampi. (A and B) Representative photomicrographs
showing CB1 staining intensity in mice and rats, respectively; (C) Mouse–rat differences in CB1 staining. Gr, stratum granulosum; M, stratum moleculare as a
whole; LM, stratum lacunosum–moleculare; O, stratum oriens. Note that the areas of the inner and outer parts of stratum moleculare are not the same; therefore,
staining intensity in the whole area is not equal to the average of inner and outer parts. *P < 0.05, at least, between mice and rats. For statistical details see text. Scale
bars, 50 lm (A and B).
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effect was similar for the two currents). However, it has been shown
that the behavioural effects of cannabinoids are produced at very low
receptor occupancy (Gifford et al., 1999). In addition, dose–response
studies for various behavioural effects of WIN-55,212 show that the
maximal effect is expressed at doses higher than 3 mg⁄kg (rats: De
Vry et al., 2004; mice: Darmani, 2001; Janoyan et al., 2002).
Moreover, the lowest dose that induced signiﬁcant effects was as high
as 20 mg⁄kg in some tests. Taken together, these data preclude
cannabinoid receptors being fully occupied during behavioural
experiments and render the IPSC–EPSC difference in WIN-55,212
sensitivity meaningful.
In rats, WIN-55,212 affected IPSCs and EPSCs with a similar
efﬁcacy. As the compound was anxiogenic in rats but the two currents
were equally affected, one has to conclude that cannabinoid effects
mediated by glutamatergic neurotransmission can override those
mediated by GABAergic mechanisms in anxiety tests (see above).
Taken together, our ﬁndings suggest that the anxiety-related effects of
cannabinoids depend on the relative cannabinoid sensitivity of
GABAergic and glutamatergic neurotransmission. When the former
prevails (e.g. in CD1 mice), cannabinoid agonists decrease anxiety.
When glutamatergic and GABAergic neurotransmission are equally
affected (e.g. in Wistar rats), the same agonist increases anxiety.
Conclusions based on behavioural ﬁndings were tested here by
electrophysiological studies performed in the hippocampus, a brain
region that is strongly involved in the control of anxiety (McNaugh-
ton, 1997; File et al., 2000). Nevertheless, fear and anxiety processing
is not restricted to this brain region. In addition, electrophysiological
experiments were performed in neonatal rodents (for technical
reasons) whereas behavioural studies were performed in young adults.
Nevertheless, this is the ﬁrst study showing that GABAergic and
glutamatergic sensitivity to cannabinoids is different in mice and rats.
One can hypothesize that similar differences exist in adult rats, have an
impact on the actions of cannabinoids and underlie their differential
effect on anxiety.
In certain CA1 subregions, CB1 receptor expression was lower in
rats than mice. However, differences were small. In addition, the
expression of CB1 receptors was larger in rats when certain subregions
of the dentate gyrus were considered. Taken together, these ﬁndings
suggest that receptor expression levels had a minor impact on species
differences in relative cannabinoid sensitivity. Such differences might
be explained by other phenomena, e.g. by differential coupling
efﬁcacies at GABAergic terminals or by differences in tonic brain
endocannabinoid levels. The latter assumption is supported by the
differential effect of AM251 in mice and rats. One can hypothesize
that the endocannabinoid tone is involved in setting the level of
transmission through GABAergic and glutamatergic synapses in the
hippocampus. The putative novel cannabinoid receptor may also be
involved. It has been repeatedly shown that CB1-KO mice respond to
cannabinoid treatments in a variety of experimental conditions
(Breivogel et al., 2001; Jarai et al., 1999; Zimmer et al., 1999; Ha ´jos
et al., 2001; Haller et al., 2002; Ko ˜falvi et al., 2003). These residual
effects of cannabinoids are unlikely to be due to the background strain
used for generating the knockout strain, or to errors in it, as they were
shown in two different CB1-KO lines generated by Ledent et al.
(1999) and Zimmer et al. (1999). Earlier, we assumed that glutamat-
ergic mechanisms are affected by cannabinoids via a novel cannabi-
noid receptor. The main support for this conclusion was that the
GABAergic effects of cannabinoids disappeared in CB1-KO mice,
whereas glutamatergic effects persisted (Ha ´jos et al., 2001; Ko ˜falvi
et al., 2003). However, the expression of the novel cannabinoid-
sensitive site may have been induced by the knockout of CB1, as a
compensatory mechanism, while in wild types CB1 could still be the
predominant receptor controlling glutamate release (Marsicano &
Lutz, 1999; Katona et al., 2006). Therefore, the identity of receptors
targeted by WIN-55,212 at glutamatergic synapses remains to be
established. At the present stage, however, one cannot exclude the
possibility that a novel receptor was involved in the species
differences shown above.
Consequences for cannabinoid physiology
The ﬁndings of the present study suggest that the behavioural effects
of cannabinoids depend on the relative responsiveness to cannabinoids
of different, often antagonistic, transmitter systems or neuron types. In
Fig. 8. A hypothesis on the mechanisms underlying the differential anxiety-related effects of cannabinoids in CD1 mice and Wistar rats. The agonist is probably
acting via CB1 receptors located on GABAergic neurons in CD1 mice. In Wistar rats, the agonist is probably acting via cannabinoid receptors located on
glutamatergic (GLU) neurons. As earlier studies suggest that glutamatergic mechanisms are affected by a novel cannabinoid receptor (CBx), but recent studies
suggest that the CB1 receptor is also located on glutamatergic cells, either the CB1 or the CBx receptor may mediate the effects of WIN-55,212 on glutamatergic
transmission. Differences seen here between CD1 mice and Wistar rats may also exist between different mouse and possibly rat strains (see Discussion).
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Wistar rats. Nevertheless, disparate studies suggest that similar
differences may exist between different mouse strains as well. For
example, Akinshola et al. (1999) showed large strain differences in the
anxiety-related effects of SR-141716A (the strains studied were ICR,
C57⁄BL6 and DBA2). In our studies, the same antagonist was
anxiolytic in maze-naive CD1 mice (Haller et al., 2002) whereas in the
study by Rodgers et al. (2003) similar effects were obtained only in
maze-experienced but not maze-naive Swiss–Webster mice. In
addition, AM-251 blocked the effect of WIN-55,212 on glutamate
release in Sprague–Dawley but not in Wistar rats (Ha ´jos & Freund,
2002; Hoffman et al., 2005). These discrepancies suggest that
differences seen here between CD1 mice and Wistar rats may also
exist between different mouse and possibly rat strains.
Conclusions
The cannabinoid agonist WIN-55,212 was anxiolytic in CD1 mice and
anxiogenic in Wistar rats. These effects are largely consistent with
earlier ﬁndings. The effects of the agonist were readily abolished by
AM-251 in mice. Surprisingly, however, AM-251 potentiated the
effects of WIN-55,212 in rats. The species-dependent effects of the
antagonist, as well as our electrophysiological studies, suggest that
WIN-55,212 affects anxiety primarily via GABAergic mechanisms in
CD1 mice and predominantly via glutamatergic mechanisms in Wistar
rats.
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